Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021
January 22 2021 - 8:00AM
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will
report its fourth quarter 2020 financial results on Wednesday,
February 17, 2021 before the U.S. financial markets open. The
company will host a conference call and simultaneous webcast at
8:00 a.m. Eastern Time that day.
Conference Call Information
The conference call can be accessed live over
the phone by dialing (833) 519-1253 or for international callers by
dialing + 1 (914) 800-3826. The passcode to access the conference
call is 7429609.
A live webcast may be accessed from the
“Investors” page of the company’s website at
https://www.royaltypharma.com/investors/news-and-events/events. A
replay of the conference call and webcast will be archived on the
company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest
buyer of biopharmaceutical royalties and a leading funder of
innovation across the biopharmaceutical industry, collaborating
with innovators from academic institutions, research hospitals and
not-for-profits through small and mid-cap biotechnology companies
to leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 45 commercial products, including AbbVie and
J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s
Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’
Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and
five development-stage product candidates. For more information,
visit www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-2295ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024